[{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"||FK506-binding protein 1A","graph1":"Oncology","graph2":"Preclinical","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Whitehawk Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Whitehawk Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Adagrasib","moa":"||GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Qiagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Qiagen","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Qiagen"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":5.7999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":5.7999999999999998,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Mirati Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":4.7999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":5.7999999999999998,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Mirati Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Adagrasib","moa":"||GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Zai Lab \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0.5,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.5,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0.34000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.34000000000000002,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Zai Lab"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Adagrasib","moa":"||GTPase KRas","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qiagen","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase III","graph3":"Qiagen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Qiagen \/ Mirati Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Qiagen \/ Mirati Therapeutics"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase III","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Mirati Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Mirati Therapeutics | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Mirati Therapeutics | Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Mirati Therapeutics | Bristol Myers Squibb"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ETOP IBCSG Partners Foundation","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase II","graph3":"ETOP IBCSG Partners Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ETOP IBCSG Partners Foundation \/ Mirati Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"ETOP IBCSG Partners Foundation \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Ryan Gentzler, MD","sponsor":"Mirati Therapeutics | University of Virginia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase II","graph3":"Ryan Gentzler, MD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ryan Gentzler, MD \/ Mirati Therapeutics | University of Virginia","highestDevelopmentStatusID":"8","companyTruncated":"Ryan Gentzler, MD \/ Mirati Therapeutics | University of Virginia"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Adagrasib","moa":"||GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Adagrasib","moa":"||GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Adagrasib","moa":"||GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0.29999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.5,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Adagrasib","moa":"||GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Adagrasib","moa":"||GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Strata Oncology","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Adagrasib","moa":"||GTPase KRas","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Strata Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Strata Oncology \/ Mirati Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Strata Oncology \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Mirati Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"7","companyTruncated":"Mirati Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zai Lab \/ Mirati Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"||GTPase KRas","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Mirati Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Verastem Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"||GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Verastem Oncology","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Verastem Oncology"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Adagrasib","moa":"||GTPase KRas","graph1":"Oncology","graph2":"Preclinical","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Whitehawk Therapeutics \/ Mirati Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Whitehawk Therapeutics \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Adagrasib","moa":"||Farnesyl transferase","graph1":"Oncology","graph2":"Phase I","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Mirati Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Kura Oncology \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"BI 1701963","moa":"||GTPase KRas (KRAS)","graph1":"Oncology","graph2":"Preclinical","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Mirati Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase II","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase I","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Mirati Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"MD Anderson Cancer Center \/ Mirati Therapeutics"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase I","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Mirati Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"MD Anderson Cancer Center \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Aadi Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase II","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirati Therapeutics \/ Aadi Bioscience","highestDevelopmentStatusID":"8","companyTruncated":"Mirati Therapeutics \/ Aadi Bioscience"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Undisclosed","graph2":"Phase I","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase I","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Mirati Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"MD Anderson Cancer Center \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Undisclosed","graph2":"Phase I","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Adagrasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase II","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirati Therapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Adagrasib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 13, 2025

                          Lead Product(s) : Adagrasib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 30, 2025

                          Lead Product(s) : Adagrasib

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : KRAZATI (adagrasib), a selective oral inhibitor of KRASG12C, is being evaluated with cetuximab for KRASG12C-mutated locally advanced or metastatic colorectal cancer.

                          Product Name : Krazati

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 04, 2024

                          Lead Product(s) : Adagrasib,Cetuximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : KRAZATI (adagrasib), a potent oral small-molecule inhibitor of KRASG12C, is indicated in combination with cetuximab for patients with locally advanced or metastatic colorectal cancer.

                          Product Name : Krazati

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 21, 2024

                          Lead Product(s) : Adagrasib,Cetuximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Krazati (adagrasib) is an oral small-molecule KRAS G12C inhibitor under evaluation for treating KRASG12C-mutated advanced/metastatic non-small cell lung cancer.

                          Product Name : Krazati

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 28, 2024

                          Lead Product(s) : Adagrasib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Krazati (adagrasib) is a selective KRAS G12C inhibitor under evaluation for KRAS G12C-mutated metastatic colorectal cancer.

                          Product Name : Krazati

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 20, 2024

                          Lead Product(s) : Adagrasib,BMS-986466,Cetuximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Ryan Gentzler, MD

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Ryan Gentzler, MD

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 08, 2024

                          Lead Product(s) : Adagrasib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Mirati Therapeutics | University of Virginia

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : BMS strengthens and diversifies oncology portfolio by gaining Krazati (adagrasib), a best-in-class KRASG12C inhibitor for advanced non-small cell lung cancer harboring a KRASG12C mutation.

                          Product Name : Krazati

                          Product Type : Other Small Molecule

                          Upfront Cash : $5,800.0 million

                          January 23, 2024

                          Lead Product(s) : Adagrasib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Bristol Myers Squibb

                          Deal Size : $5,800.0 million

                          Deal Type : Acquisition

                          blank

                          09

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : KRAZATI (adagrasib) is a selective oral KRASG12C inhibitor, currently in Phase III trials for treating locally advanced or metastatic non-small cell lung cancer.

                          Product Name : Krazati

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 04, 2024

                          Lead Product(s) : Adagrasib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Bristol Myers Squibb

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          MD Anderson Cancer Center

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          MD Anderson Cancer Center

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 14, 2023

                          Lead Product(s) : Adagrasib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Mirati Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank